In order to establish a combined predictive diagnosis model of NSCLC BM based on serum levels of CTSF and FBLN1, we used patients in cohort 2 (LCBM and each control group) as the training dataset, and included another set of 160 patients (cohort 4: 44 LCBM and 116 controls) as validation dataset to verify the stability of the constructed predictive model. The gene discussed is FBLN1; the disease is non-small cell lung carcinoma.